STOCK TITAN

Coeptis Therapeutics Inc - COEP STOCK NEWS

Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.

About Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) is a diversified biopharmaceutical and technology company headquartered in Wexford, Pennsylvania. The company is pioneering innovative cell therapy platforms targeting cancer, autoimmune, and infectious diseases, while simultaneously leveraging cutting-edge technologies such as artificial intelligence (AI), robotic process automation (RPA), and blockchain to drive operational efficiency and expand into new markets.

Biopharmaceutical Innovations

At its core, Coeptis is focused on developing transformative cell therapy solutions that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its therapeutic portfolio includes:

  • SNAP-CAR Technology: A universal, multi-antigen CAR T-cell platform licensed from the University of Pittsburgh, designed to enhance the efficacy and safety of CAR T-cell therapies.
  • CD38-GEAR-NK and CD38-Diagnostic Platforms: Developed in collaboration with VyGen-Bio and Karolinska Institutet, these platforms target CD38-related cancers, offering both therapeutic and diagnostic capabilities.
  • Allogeneic Cellular Immunotherapy: Assets licensed from Deverra Therapeutics, including DVX201, an unmodified natural killer (NK) cell therapy currently in clinical trials.

The company employs a strategic business model that maximizes the value of its biopharmaceutical assets through in-licensing, out-licensing, co-development agreements, and partnerships with leading research institutions.

Technology-Driven Expansion

In recent years, Coeptis has expanded its focus to include technology-driven solutions, establishing a dedicated Technology Division. This division integrates advanced AI and RPA tools to optimize operations and enhance decision-making processes. Key initiatives include:

  • NexGenAI Affiliates Network: An AI-powered marketing platform acquired to streamline marketing efforts through automation, predictive analytics, and data-driven insights. This platform enables businesses to optimize campaigns and improve customer engagement in highly regulated industries like biotech and pharmaceuticals.
  • Blockchain Integration: Partnerships with blockchain developers, such as Arketyp Valu, to integrate scalable blockchain solutions into digital marketing platforms, enhancing security and transparency.
  • COEP Venture Group: An investment arm focused on funding startups specializing in AI, RPA, and intelligent automation, further diversifying the company’s growth potential.

Strategic Partnerships and Market Position

Coeptis has strategically aligned itself with leading organizations to enhance its capabilities and market reach. Notable collaborations include:

  • Partnerships with academic institutions like the University of Pittsburgh and Karolinska Institutet for cutting-edge research and development.
  • Acquisitions such as NexGenAI Affiliates Network to integrate AI-driven marketing tools into its operations.
  • Collaborations with blockchain projects like Verus Coin to explore decentralized solutions for digital marketing.

These partnerships underline Coeptis’ commitment to innovation and its ability to adapt to emerging market trends.

Challenges and Opportunities

While Coeptis operates in highly competitive and regulated sectors, its dual focus on biopharmaceutical development and technology innovation provides a unique value proposition. The integration of advanced technologies into its operational framework not only enhances efficiency but also opens new revenue streams, positioning the company as a forward-thinking leader in both industries.

Conclusion

Coeptis Therapeutics Holdings Inc. represents a compelling blend of biopharmaceutical innovation and technological advancement. By combining groundbreaking cell therapy platforms with state-of-the-art AI and blockchain solutions, the company is well-positioned to address complex healthcare challenges while exploring new growth opportunities in technology-driven markets.

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has entered into a definitive agreement for a private placement of 2,000,000 shares of its common stock, with expected gross proceeds of $2,000,000. The company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
Rhea-AI Summary
Coeptis expands exclusive license agreement with University of Pittsburgh for SNAP-CAR technology platform in NK cells. Also obtains exclusive rights to negotiate acquisition of GEAR™ cell therapy and companion diagnostic platforms from VyGen Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. to participate in panel on emerging cell and gene therapies at BioFlorida Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences acquisition
Rhea-AI Summary
Coeptis Therapeutics announces acceptance of abstract involving SNAP-CAR for presentation at SITC 2023, validating its potential in cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. announces presentation at 2023 Cell & Gene Meeting on the Mesa. Dr. Delaney to discuss positive safety results for DVX201 in AML, MDS, and COVID-19 patients. Virtual attendance available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.31%
Tags
conferences
-
Rhea-AI Summary
Coeptis Therapeutics reports positive safety results for DVX201 cell therapy in Phase 1 trials for AML, MDS, and COVID-19 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
clinical trial covid-19
Rhea-AI Summary
Deverra Therapeutics receives grants totaling $3.5 million for CAR-NK and myeloid cell programs in cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none
-
Rhea-AI Summary
Coeptis Therapeutics has appointed Dr. Colleen Delaney as its Chief Scientific and Medical Officer after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs. Dr. Delaney brings over two decades of experience in oncology and stem cell transplant, with expertise in cell therapy product development. She will lead Coeptis in developing off-the-shelf cellular immunotherapies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
management
-
Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has acquired key assets from Deverra Therapeutics Inc. to bolster its pipeline. The transaction includes two Phase 1 clinical stage assets for NK cell therapies in acute myeloid leukemia and respiratory infections. Coeptis also gains a scalable allogeneic cellular immunotherapy platform. The company paid $570,000 in cash and issued 4,000,000 shares of common stock to Deverra.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Coeptis Therapeutics (COEP)?

The current stock price of Coeptis Therapeutics (COEP) is $10.594 as of March 7, 2025.

What is the market cap of Coeptis Therapeutics (COEP)?

The market cap of Coeptis Therapeutics (COEP) is approximately 33.2M.

What does Coeptis Therapeutics Holdings specialize in?

Coeptis specializes in developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, while also leveraging AI and blockchain technologies for operational growth.

What is SNAP-CAR technology?

SNAP-CAR is a universal, multi-antigen CAR T-cell platform licensed from the University of Pittsburgh, aimed at improving the safety and efficacy of CAR T-cell therapies.

How does Coeptis integrate AI into its business model?

Coeptis utilizes AI through its NexGenAI Affiliates Network, an AI-powered marketing platform designed to optimize campaigns, enhance customer engagement, and streamline operations.

What is the role of blockchain in Coeptis’ operations?

Coeptis integrates blockchain technologies to enhance security and scalability in digital marketing platforms, collaborating with projects like Verus Coin and ValuSocial.

What is COEP Venture Group?

COEP Venture Group is Coeptis’ investment arm focused on funding startups specializing in AI, robotic process automation, and intelligent systems to drive technological advancements.

Who are Coeptis’ key partners?

Coeptis collaborates with institutions like the University of Pittsburgh, Karolinska Institutet, and technology developers such as NexGenAI and Arketyp Valu.

How does Coeptis generate revenue?

Coeptis generates revenue through licensing agreements, co-development partnerships, and technology-driven solutions like AI-powered marketing platforms.

What industries does Coeptis operate in?

Coeptis operates in the biopharmaceutical and technology sectors, focusing on cell therapy, AI-driven marketing, and blockchain integration.

What sets Coeptis apart from competitors?

Coeptis’ unique integration of biopharmaceutical innovation with advanced technologies like AI and blockchain differentiates it from competitors in both sectors.

Where is Coeptis headquartered?

Coeptis is headquartered in Wexford, Pennsylvania.
Coeptis Therapeutics Inc

Nasdaq:COEP

COEP Rankings

COEP Stock Data

33.23M
2.63M
18.53%
4.28%
0.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WEXFORD